The development of nonarteritic anterior ischaemic optic neuropathy has been described to
phosphodiesterase type 5 inhibitors. The aim of this systematic review and meta‐analysis …

Background: Use of phosphodiesterase-5 (PDE-5) inhibitors has been reported to be a risk
factor for development of nonarteritic anterior ischemic optic neuropathy (NAION) in males …

Introduction Phosphodiesterase type 5 inhibitors (PDE5-Is) are first-line drugs for erectile
dysfunction. Non-arteritic anterior ischemic optic neuropathy (NAION) has been linked with …

Phosphodiesterase type 5 (PDE5) inhibitor drugs for erectile dysfunction have
revolutionised the treatment of male sexual dysfunction and are among the best selling …

Abstract Phosphodiesterase type 5 (PDE5) inhibitors are frequently used for erectile
dysfunction (ED) as the first line of treatment. This medication was initially developed to treat …

Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic
neuropathy and one of the most common causes of sudden vision loss in the elderly …

Background: The cause of nonarteritic anterior ischaemic optic neuropathy (ION) is
unknown, although assumed to be related to transient vascular insufficiency of the optic …

Introduction Nonarteritic anterior ischemic optic neuropathy (NAION), a rare visual disorder,
has been reported in men using phosphodiesterase type 5 inhibitors (PDE5i) for erectile …

Abstract Phosphodiesterase type-5 (PDE-5) inhibitors are well tolerated and efficacious
treatments for male erectile dysfunction that currently rank among the best-selling drugs …

PURPOSE: To determine the feasibility of a case-control study of phosphodiesterase (PDE)-
5 inhibitors and nonarteritic ischemic optic neuropathy (NION). DESIGN: Retrospective …